Publication of Final Terms of EMTN Notes

Source: RNS
RNS Number : 6838H
GSK Capital B.V.
25 November 2022

Issued: 25 November 2022, London UK - LSE Announcement

Publication of Final Terms

GSK Capital B.V. announces that the following final terms dated 25 November 2022 (the "Final Terms") in respect of the Notes (as defined below) are available for viewing:

GSK Capital B.V. issue of:

EUR 500,000,000 3.000% Notes due 2027; and

EUR 750,000,000 3.125% Notes due 2032.

in each case guaranteed by GSK plc issued under the £20,000,000,000 Euro Medium Term Note Programme (the "Notes")

Copies of the Final Terms have been submitted to the Financial Conduct Authority's NSM submission portal via the Electronic Submission System (ESS). A copy can be viewed at:

For further information, please contact:

GSK plc
980 Great West Road
United Kingdom


UK Media enquiries:

Tim Foley

+44 (0) 20 8047 5564

European Analyst/Investor enquiries:

Nick Stone

James Dodwell

+44 (0) 7717 618 834

+44 (0) 7881 269 066



Please note that the information contained in the Final Terms and the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

GSK Capital B.V.

Registered in the Netherlands and in the UK as an overseas company:

No. FC038264

Registered UK establishment:

980 Great West Road

Brentford, Middlesex



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.